Galapagos loses partner on inflammatory bowel drug

By Reuters

Dec 16, 2014 08:15 AM EST

Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a program to develop a new drug to treat bowel disease.

Galapagos said it had received all rights to the GPR84 inhibitor program which included the drug GLPG1205 and said it would continue with a phase 2 study of its own on patients with inflammatory bowel disease ulcerative colitis.

The group gave no financial details about the transaction.

It still has a string of drugs developments in its pipeline with pharmaceutical groups such as AbbVie, GSK and Servier.

© 2024 VCPOST, All rights reserved. Do not reproduce without permission.

Join the Conversation

Real Time Analytics